Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03, Fidelity Earnings reports.
Shares of MBRX opened at $0.84 on Friday. The stock has a market cap of $52.46 million, a price-to-earnings ratio of -2.33 and a beta of 2.18. Moleculin Biotech has a 12 month low of $0.32 and a 12 month high of $1.97. The company has a 50-day moving average price of $0.77 and a two-hundred day moving average price of $0.94.
Separately, Zacks Investment Research cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Friday.
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.